Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. GRI Bio's Pre-Tax Income for the
three
months ended in Dec. 2024 was $-1.95 Mil. GRI Bio's Revenue for the
three
months ended in Dec. 2024 was $0.00 Mil. Therefore, GRI Bio's pretax margin for the quarter that ended in Dec. 2024 was %.
The historical rank and industry rank for GRI Bio's Pretax Margin % or its related term are showing as below:
GRI's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -137.15 * Ranked among companies with meaningful Pretax Margin % only.
GRI Bio Pretax Margin % Historical Data
The historical data trend for GRI Bio's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of GRI Bio's Pretax Margin %
For the Biotechnology subindustry, GRI Bio's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRI Bio's Pretax Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GRI Bio's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where GRI Bio's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRI Bio (NAS:GRI) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
GRI Bio Pretax Margin % Related Terms
Thank you for viewing the detailed overview of GRI Bio's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GRI has been successfully added to your 